|
AU759779B2
(en)
*
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
EP2180007B2
(en)
*
|
1998-04-20 |
2017-08-30 |
Roche Glycart AG |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
|
EP2264166B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
US7863020B2
(en)
|
2000-06-28 |
2011-01-04 |
Glycofi, Inc. |
Production of sialylated N-glycans in lower eukaryotes
|
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
NZ581474A
(en)
|
2001-08-03 |
2011-04-29 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
US7691810B2
(en)
|
2003-10-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Method of producing recombinant antithrombin III composition
|
|
DK1716181T3
(en)
|
2004-02-19 |
2010-03-01 |
Genentech Inc |
CDR repaired antibodies
|
|
MXPA06014069A
(en)
|
2004-06-04 |
2007-04-25 |
Genentech Inc |
Method for treating multiple sclerosis.
|
|
RU2411956C2
(en)
|
2004-10-05 |
2011-02-20 |
Дженентек, Инк. |
Method of treating vasculitis
|
|
JO3000B1
(en)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
Antibody Formulations.
|
|
JP2008528486A
(en)
|
2005-01-21 |
2008-07-31 |
ジェネンテック・インコーポレーテッド |
Fixed dose of HER antibody
|
|
ZA200707078B
(en)
|
2005-02-23 |
2008-11-26 |
Genentech Inc |
Extending time to disease progression or survival in cancer patients
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
KR101453570B1
(en)
|
2005-12-02 |
2014-10-22 |
제넨테크, 인크. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
|
CA2638785C
(en)
|
2006-01-05 |
2017-02-21 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using same
|
|
AR059851A1
(en)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
ANTIBODIES OF EGFL7 AND METHODS OF USE
|
|
MX2008015132A
(en)
|
2006-05-30 |
2008-12-10 |
Genentech Inc |
Antibodies and immunoconjugates and uses therefor.
|
|
KR20090027227A
(en)
|
2006-06-06 |
2009-03-16 |
제넨테크, 인크. |
Anti-dll4 antibodies and methods using same
|
|
EP2046809B1
(en)
|
2006-07-19 |
2016-12-07 |
The Trustees Of The University Of Pennsylvania |
Wsx-1/il-27 as a target for anti-inflammatory responses
|
|
RS53861B1
(en)
*
|
2006-09-10 |
2015-08-31 |
Glycotope Gmbh |
Use of human cells of myeloid leukaemia origin for expression of antibodies
|
|
LT2845866T
(en)
|
2006-10-27 |
2017-07-10 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
PL1920781T3
(en)
|
2006-11-10 |
2015-06-30 |
Glycotope Gmbh |
Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
|
|
BRPI0806403A2
(en)
|
2007-02-09 |
2011-09-06 |
Genentech Inc |
anti-robo4 antibody, use an antibody and imaging method
|
|
PL2132573T3
(en)
|
2007-03-02 |
2014-09-30 |
Genentech Inc |
Predicting response to a her dimerisation inhbitor based on low her3 expression
|
|
ES2417148T3
(en)
|
2007-06-08 |
2013-08-06 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
KR101922788B1
(en)
|
2007-09-26 |
2018-11-27 |
추가이 세이야쿠 가부시키가이샤 |
Modified antibody constant region
|
|
PT2514436T
(en)
|
2007-11-07 |
2018-03-21 |
Genentech Inc |
Il-22 for use in treating microbial disorders
|
|
AR069501A1
(en)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR)
|
|
TWI472339B
(en)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
|
|
TW201438738A
(en)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
|
SG10201605250SA
(en)
|
2008-10-14 |
2016-08-30 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
|
DK2752189T3
(en)
|
2008-11-22 |
2017-01-16 |
Hoffmann La Roche |
APPLICATION OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
CN102264759B
(en)
|
2008-12-23 |
2016-05-11 |
弗·哈夫曼-拉罗切有限公司 |
Immunoglobulin variants with the Binding change of albumin A
|
|
US8597652B2
(en)
|
2009-03-20 |
2013-12-03 |
Genentech, Inc. |
Multispecific anti-HER antibodies
|
|
BRPI1006270B1
(en)
|
2009-03-25 |
2022-08-16 |
Genentech, Inc |
ANTI-A5SS1 ANTIBODY, IMMUNOCONJUGATE, PHARMACEUTICAL COMPOSITION, IN VITRO OR EX VIVO METHOD TO DETECT A5SS1 PROTEIN, USE OF AN ANTIBODY AND KIT TO DETECT A5SS1 PROTEIN
|
|
HRP20221471T1
(en)
|
2009-03-25 |
2023-02-03 |
Genentech, Inc. |
Anti-fgfr3 antibodies and methods using same
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US20100316639A1
(en)
|
2009-06-16 |
2010-12-16 |
Genentech, Inc. |
Biomarkers for igf-1r inhibitor therapy
|
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
|
US20110027275A1
(en)
|
2009-07-31 |
2011-02-03 |
Napoleone Ferrara |
Inhibition of tumor metastasis
|
|
AR077848A1
(en)
|
2009-08-15 |
2011-09-28 |
Genentech Inc |
ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF BREAST CANCER PREVIOUSLY TREATED
|
|
WO2011028950A1
(en)
|
2009-09-02 |
2011-03-10 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
JP5814925B2
(en)
|
2009-10-22 |
2015-11-17 |
ジェネンテック， インコーポレイテッド |
Anti-hepsin antibody and method of use thereof
|
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
|
WO2011056997A1
(en)
|
2009-11-04 |
2011-05-12 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
|
CA2780143A1
(en)
|
2009-11-05 |
2011-05-12 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
|
DK2516465T3
(en)
|
2009-12-23 |
2016-06-06 |
Hoffmann La Roche |
ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF
|
|
JP5841072B2
(en)
|
2010-02-10 |
2016-01-06 |
イミュノジェン・インコーポレーテッド |
CD20 antibody and use thereof
|
|
SG183333A1
(en)
|
2010-02-18 |
2012-09-27 |
Genentech Inc |
Neuregulin antagonists and use thereof in treating cancer
|
|
EP2539367A2
(en)
|
2010-02-23 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Anti-angiogenesis therapy for the treatment of ovarian cancer
|
|
EP2550295A1
(en)
|
2010-03-24 |
2013-01-30 |
F. Hoffmann-La Roche AG |
Anti-lrp6 antibodies
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
|
CA2795972A1
(en)
|
2010-06-03 |
2011-12-08 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
|
MX336001B
(en)
|
2010-06-18 |
2016-01-07 |
Genentech Inc |
Anti-axl antibodies and methods of use.
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
AU2011274528B2
(en)
|
2010-07-09 |
2015-04-23 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
WO2012012750A1
(en)
|
2010-07-23 |
2012-01-26 |
Trustees Of Boston University |
ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
|
|
JP2013541501A
(en)
|
2010-08-03 |
2013-11-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Biomarkers for chronic lymphocytic leukemia (CLL)
|
|
CA2805564A1
(en)
|
2010-08-05 |
2012-02-09 |
Stefan Jenewein |
Anti-mhc antibody anti-viral cytokine fusion protein
|
|
NZ703653A
(en)
|
2010-08-13 |
2016-09-30 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
|
KR101653030B1
(en)
|
2010-08-13 |
2016-08-31 |
로슈 글리카트 아게 |
Anti-tenascin-c a2 antibodies and methods of use
|
|
NZ604510A
(en)
|
2010-08-17 |
2013-10-25 |
Csl Ltd |
Dilutable biocidal compositions and methods of use
|
|
JP5813114B2
(en)
|
2010-08-25 |
2015-11-17 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Antibodies against IL-18R1 and uses thereof
|
|
CA2808236A1
(en)
|
2010-08-31 |
2012-03-08 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
|
AU2011312205B2
(en)
|
2010-10-05 |
2015-08-13 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
|
JP2013541594A
(en)
|
2010-11-08 |
2013-11-14 |
ジェネンテック， インコーポレイテッド |
Anti-IL-6 receptor antibody administered subcutaneously
|
|
PE20140238A1
(en)
|
2010-11-10 |
2014-03-07 |
Genentech Inc |
METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY FOR NEURAL DISEASE
|
|
CN110251668A
(en)
|
2010-11-30 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
Low-affinity blood-brain barrier receptor antibody and application thereof
|
|
MY188365A
(en)
|
2010-12-16 |
2021-12-06 |
Genentech Inc |
Diagnosis and treatments relating to th2 inhibition
|
|
UA115641C2
(en)
|
2010-12-20 |
2017-11-27 |
Дженентек, Інк. |
DETERMINED ANTIBODY Binds Mesothelin and Immunoconjugate Containing It
|
|
KR20130118925A
(en)
|
2010-12-22 |
2013-10-30 |
제넨테크, 인크. |
Anti-pcsk9 antibodies and methods of use
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
|
CA2825081A1
(en)
|
2011-02-28 |
2012-09-07 |
Birgit Bossenmaier |
Antigen binding proteins
|
|
EP2691417B1
(en)
|
2011-03-29 |
2018-08-01 |
Roche Glycart AG |
Antibody fc variants
|
|
KR20140021589A
(en)
|
2011-04-07 |
2014-02-20 |
제넨테크, 인크. |
Anti-fgfr4 antibodies and methods of use
|
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
|
WO2012155019A1
(en)
|
2011-05-12 |
2012-11-15 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
|
LT2710035T
(en)
|
2011-05-16 |
2017-06-26 |
F. Hoffmann-La Roche Ag |
Fgfr1 agonists and methods of use
|
|
EP2721067B1
(en)
|
2011-06-15 |
2019-07-31 |
F.Hoffmann-La Roche Ag |
Anti-human epo receptor antibodies and methods of use
|
|
EA201400046A1
(en)
|
2011-06-22 |
2014-07-30 |
Ф. Хоффманн-Ля Рош Аг |
REMOVAL OF TARGET CELLS WITH THE HELP OF CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING THE CONTAINING GCGS CLASS I COMPLEX
|
|
CN107090038A
(en)
|
2011-06-30 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
Anti- C MET antibody formulations
|
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
|
MX2014001766A
(en)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Neuregulin antibodies and uses thereof.
|
|
MX2014001736A
(en)
|
2011-08-17 |
2014-03-31 |
Genentech Inc |
Inhibition of angiogenesis in refractory tumors.
|
|
EP2748302B1
(en)
|
2011-08-22 |
2018-08-15 |
Glycotope GmbH |
Microorganisms carrying a tumor antigen
|
|
CA2844141A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
|
WO2013040433A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
|
AR087918A1
(en)
|
2011-09-19 |
2014-04-23 |
Genentech Inc |
COMBINED TREATMENTS INCLUDING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS
|
|
JP2014531210A
(en)
|
2011-09-30 |
2014-11-27 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
Antibodies against TL1a and uses thereof
|
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
|
JP5854535B2
(en)
*
|
2011-10-05 |
2016-02-09 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Methods for the production of antibody G1 glycoforms
|
|
ES2687951T3
(en)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anti-HtrA1 antibodies and procedures for use
|
|
MX2014004426A
(en)
|
2011-10-15 |
2014-07-09 |
Genentech Inc |
Scd1 antagonists for treating cancer.
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
IN2014CN03062A
(en)
|
2011-10-28 |
2015-07-31 |
Hoffmann La Roche |
|
|
JP2015504413A
(en)
|
2011-10-28 |
2015-02-12 |
パトリス リミテッド |
PAT-LM1 epitope and methods for using the same
|
|
RU2014124842A
(en)
|
2011-11-21 |
2015-12-27 |
Дженентек, Инк. |
CLEANING ANTI-C-MET ANTIBODIES
|
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
|
SG11201403223PA
(en)
|
2011-12-22 |
2014-07-30 |
Hoffmann La Roche |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
|
CN113896787A
(en)
|
2011-12-22 |
2022-01-07 |
弗·哈夫曼-拉罗切有限公司 |
Expression vector element combinations, novel production cell production methods and their use in the recombinant production of polypeptides
|
|
MX2014007262A
(en)
|
2011-12-22 |
2014-08-01 |
Hoffmann La Roche |
Full length antibody display system for eukaryotic cells and its use.
|
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
|
CN104411717A
(en)
|
2012-01-09 |
2015-03-11 |
斯克利普斯研究所 |
Humanized antibodies with ultralong CDR3S
|
|
EP2804630B1
(en)
|
2012-01-18 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Methods of using fgf19 modulators
|
|
PE20141561A1
(en)
|
2012-01-18 |
2014-11-12 |
Genentech Inc |
ANTI-LRP5 ANTIBODIES AND METHODS OF USE
|
|
EP2812350B1
(en)
|
2012-02-11 |
2019-04-03 |
F.Hoffmann-La Roche Ag |
R-spondin translocations and methods using the same
|
|
TR201808458T4
(en)
|
2012-02-15 |
2018-07-23 |
Hoffmann La Roche |
FC-receptor based affinity chromatography.
|
|
SG11201406079TA
(en)
|
2012-03-27 |
2014-10-30 |
Genentech Inc |
Diagnosis and treatments relating to her3 inhibitors
|
|
AR090549A1
(en)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
ANTI-LGR5 AND IMMUNOCATE PLAYERS
|
|
KR20150006000A
(en)
|
2012-05-01 |
2015-01-15 |
제넨테크, 인크. |
Anti-pmel17 antibodies and immunoconjugates
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
CA2873646C
(en)
|
2012-05-18 |
2022-04-26 |
Genentech, Inc. |
High-concentration monoclonal antibody formulations
|
|
BR112014028838A2
(en)
|
2012-05-21 |
2020-05-12 |
Genentech Inc |
USES OF AN ANTIBODY, METHOD FOR MAKING AN ANTIBODY AND ANTIBODIES
|
|
WO2013177470A1
(en)
|
2012-05-23 |
2013-11-28 |
Genentech, Inc. |
Selection method for therapeutic agents
|
|
WO2013181568A2
(en)
*
|
2012-06-01 |
2013-12-05 |
Momenta Pharmaceuticals, Inc. |
Methods related to alemtuzumab
|
|
US9695244B2
(en)
|
2012-06-01 |
2017-07-04 |
Momenta Pharmaceuticals, Inc. |
Methods related to denosumab
|
|
EP2861624A1
(en)
|
2012-06-15 |
2015-04-22 |
F. Hoffmann-La Roche AG |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
PL2869837T3
(en)
|
2012-07-04 |
2017-03-31 |
F.Hoffmann-La Roche Ag |
Anti-theophylline antibodies and methods of use
|
|
EP3138580B1
(en)
|
2012-07-04 |
2021-03-03 |
F. Hoffmann-La Roche AG |
Covalently linked antigen-antibody conjugates
|
|
KR20150030755A
(en)
|
2012-07-04 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
Anti-biotin antibodies and methods of use
|
|
JP6309518B2
(en)
|
2012-07-05 |
2018-04-11 |
ジェネンテック， インコーポレイテッド |
Expression and secretion system
|
|
KR20150030753A
(en)
|
2012-07-09 |
2015-03-20 |
제넨테크, 인크. |
Immunoconjugates comprising anti-cd79b antibodies
|
|
EA201590173A1
(en)
|
2012-07-09 |
2015-09-30 |
Дженентек, Инк. |
IMMUNOCONGUTS CONTAINING ANTIBODIES TO CD22
|
|
EP2869849A1
(en)
|
2012-07-09 |
2015-05-13 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
|
MX2015000314A
(en)
|
2012-07-09 |
2015-04-10 |
Genentech Inc |
Immunoconjugates comprising anti - cd79b antibodies.
|
|
SI3495387T1
(en)
|
2012-07-13 |
2021-12-31 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
KR20190121874A
(en)
|
2012-08-29 |
2019-10-28 |
에프. 호프만-라 로슈 아게 |
Blood brain barrier shuttle
|
|
CA2890207A1
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
|
PE20150956A1
(en)
|
2012-11-08 |
2015-06-20 |
Hoffmann La Roche |
HER3 FORK BINDING HER3 ANTIGEN BINDING PROTEINS
|
|
EA201590731A1
(en)
|
2012-11-13 |
2015-11-30 |
Дженентек, Инк. |
ANTIBODIES TO HEMAGGLUTININ AND METHODS OF APPLICATION
|
|
JP6475167B2
(en)
|
2012-12-21 |
2019-02-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Multifunctional protein containing disulfide-linked multivalent MHC class I
|
|
CA2898326C
(en)
|
2013-01-18 |
2022-05-17 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
KR102204127B1
(en)
|
2013-02-01 |
2021-01-20 |
키라 바이오테크 피티와이 리미티드 |
Anti-cd83 antibodies and use thereof
|
|
DK2953971T3
(en)
|
2013-02-07 |
2023-05-01 |
Csl Ltd |
IL-11R BINDING PROTEINS AND USES THEREOF
|
|
CN104994879A
(en)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
Methods of treating cancer and preventing drug resistance
|
|
CA2896259A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
|
CA2902263A1
(en)
|
2013-03-06 |
2014-09-12 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
RU2015139054A
(en)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
METHODS FOR TREATING CANCER AND PREVENTION OF DRUG RESISTANCE OF CANCER
|
|
KR20150127199A
(en)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
|
MX2015012326A
(en)
|
2013-03-15 |
2016-03-08 |
Genentech Inc |
Anti-crth2 antibodies and their use.
|
|
KR20150128707A
(en)
|
2013-03-15 |
2015-11-18 |
제넨테크, 인크. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
EP2968537A1
(en)
|
2013-03-15 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
SI2970422T1
(en)
|
2013-03-15 |
2018-07-31 |
F. Hoffmann-La Roche Ag |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
|
SG11201507333XA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
|
US9598485B2
(en)
|
2013-03-15 |
2017-03-21 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
|
UA118028C2
(en)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
|
|
TWI747803B
(en)
|
2013-04-29 |
2021-12-01 |
瑞士商赫孚孟拉羅股份公司 |
Human fcrn-binding modified antibodies and methods of use
|
|
MX2015015060A
(en)
|
2013-04-29 |
2016-02-25 |
Hoffmann La Roche |
Fc-receptor binding modified asymmetric antibodies and methods of use.
|
|
EP3327034A1
(en)
|
2013-04-29 |
2018-05-30 |
F. Hoffmann-La Roche AG |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
|
PL3594240T3
(en)
|
2013-05-20 |
2024-04-02 |
F. Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
CN111518199A
(en)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
Humanized antibodies with ultralong complementarity determining regions
|
|
MX2016001236A
(en)
|
2013-08-01 |
2016-05-24 |
Five Prime Therapeutics Inc |
Afucosylated anti-fgfr2iiib antibodies.
|
|
SG11201601044XA
(en)
|
2013-08-12 |
2016-03-30 |
Genentech Inc |
Compositions and method for treating complement-associated conditions
|
|
CA2922889A1
(en)
|
2013-09-17 |
2015-03-26 |
Genentech, Inc. |
Methods of using anti-lgr5 antibodies
|
|
JP2016537965A
(en)
|
2013-10-11 |
2016-12-08 |
ジェネンテック， インコーポレイテッド |
NSP4 inhibitors and methods of use
|
|
KR20160044060A
(en)
|
2013-10-11 |
2016-04-22 |
에프. 호프만-라 로슈 아게 |
Multispecific domain exchanged common variable light chain antibodies
|
|
MX2016003744A
(en)
|
2013-10-11 |
2016-08-11 |
Us Health |
Tem8 antibodies and their use.
|
|
CA2925598A1
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
|
MX2016005159A
(en)
|
2013-10-23 |
2016-07-05 |
Genentech Inc |
Methods of diagnosing and treating eosinophilic disorders.
|
|
RU2697098C1
(en)
|
2013-11-21 |
2019-08-12 |
Ф.Хоффманн-Ля Рош Аг |
Antibodies to alpha-synuclein and methods of using
|
|
SG10201808835QA
(en)
|
2013-12-09 |
2018-11-29 |
Allakos Inc |
Anti-siglec-8 antibodies and methods of use thereof
|
|
US20160333063A1
(en)
|
2013-12-13 |
2016-11-17 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
|
MX2016007576A
(en)
|
2013-12-13 |
2016-10-03 |
Genentech Inc |
Anti-cd33 antibodies and immunoconjugates.
|
|
RU2719487C2
(en)
|
2013-12-17 |
2020-04-17 |
Дженентек, Инк. |
Methods of treating cancer using antagonists binding to components of the signal path pd-1, and taxanes
|
|
PE20210107A1
(en)
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
ANTI-CD3 ANTIBODIES AND METHODS OF USE
|
|
EP3527587A1
(en)
|
2013-12-17 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
|
|
CN105899535A
(en)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
|
TWI728373B
(en)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
Antibodies and methods of use
|
|
CN105873616B
(en)
|
2014-01-03 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
Covalently linked polypeptide toxin-antibody conjugates
|
|
CN105873615B
(en)
|
2014-01-03 |
2020-12-25 |
豪夫迈·罗氏有限公司 |
Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
JP6476194B2
(en)
|
2014-01-03 |
2019-02-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Bispecific anti-hapten / anti-blood brain barrier receptor antibodies, complexes thereof, and their use as blood brain barrier shuttles
|
|
MX2016008190A
(en)
|
2014-01-06 |
2016-10-21 |
Hoffmann La Roche |
Monovalent blood brain barrier shuttle modules.
|
|
KR20160107190A
(en)
|
2014-01-15 |
2016-09-13 |
에프. 호프만-라 로슈 아게 |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
US20170043034A1
(en)
|
2014-01-24 |
2017-02-16 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
AU2015214058B2
(en)
|
2014-02-08 |
2020-07-09 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
|
EP3102230B1
(en)
|
2014-02-08 |
2021-04-28 |
F. Hoffmann-La Roche AG |
Methods of treating alzheimer's disease
|
|
ES2685424T3
(en)
|
2014-02-12 |
2018-10-09 |
F. Hoffmann-La Roche Ag |
Anti-Jagged1 antibodies and procedures for use
|
|
WO2015127405A2
(en)
|
2014-02-21 |
2015-08-27 |
Genentech, Inc. |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
|
EP3110446B1
(en)
|
2014-02-28 |
2021-12-01 |
Allakos Inc. |
Methods and compositions for treating siglec-8 associated diseases
|
|
CN106103730B
(en)
|
2014-03-14 |
2021-06-08 |
豪夫迈·罗氏有限公司 |
Methods and compositions for secretion of heterologous polypeptides
|
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
BR112016021383A2
(en)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
METHOD TO IDENTIFY A PATIENT WITH CANCER WHO IS LIKE OR LESS LIKELY TO RESPOND TO TREATMENT WITH A CMET ANTAGONIST, METHOD TO IDENTIFY A PATIENT WITH PREVIOUSLY TREATED CANCER, METHOD TO DETERMINE THE EXPRESSION OF THE HGF BIOMARKER, ANTI-C-MET ANTAGONIST AND ITS USE, DIAGNOSTIC KIT AND ITS PREPARATION METHOD
|
|
JP6588461B2
(en)
|
2014-03-31 |
2019-10-09 |
ジェネンテック， インコーポレイテッド |
Combination therapy comprising an anti-angiogenic agent and an OX40 binding agonist
|
|
UA121112C2
(en)
|
2014-03-31 |
2020-04-10 |
Дженентек, Інк. |
Anti-ox40 antibodies and methods of use
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
KR20170003582A
(en)
|
2014-05-22 |
2017-01-09 |
제넨테크, 인크. |
Anti-gpc3 antibodies and immunoconjugates
|
|
JP2017524371A
(en)
|
2014-05-23 |
2017-08-31 |
ジェネンテック， インコーポレイテッド |
MIT biomarkers and methods of use
|
|
WO2015191715A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
MX2016015280A
(en)
|
2014-06-26 |
2017-03-03 |
Hoffmann La Roche |
Anti-brdu antibodies and methods of use.
|
|
AU2015288232B2
(en)
|
2014-07-11 |
2020-10-15 |
Ventana Medical Systems, Inc. |
Anti-PD-L1 antibodies and diagnostic uses thereof
|
|
WO2016007775A1
(en)
|
2014-07-11 |
2016-01-14 |
Genentech, Inc. |
Notch pathway inhibition
|
|
TWI751102B
(en)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
Antibodies and chimeric antigen receptors specific for cd19
|
|
EP4074735A1
(en)
|
2014-08-28 |
2022-10-19 |
BioAtla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
EP3191527B1
(en)
*
|
2014-09-10 |
2020-01-15 |
F.Hoffmann-La Roche Ag |
Galactoengineered immunoglobulin 1 antibodies
|
|
SG10201804931QA
(en)
|
2014-09-12 |
2018-07-30 |
Genentech Inc |
Anti-cll-1 antibodies and immunoconjugates
|
|
PE20170935A1
(en)
|
2014-09-12 |
2017-07-13 |
Genentech Inc |
ANTI-HER2 AND IMMUNOCONJUGATED ANTIBODIES
|
|
AR101848A1
(en)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
ANTI-B7-H4 AND IMMUNOCATE PLAYERS
|
|
CA2957148A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
|
DK3262071T3
(en)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Method of using anti-CD79b immune conjugates
|
|
CN107074938A
(en)
|
2014-10-16 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
Anti alpha synapse nucleoprotein antibody and application method
|
|
AU2015336931B2
(en)
|
2014-10-23 |
2021-04-29 |
Kira Biotech Pty Limited |
CD83 binding proteins and uses thereof
|
|
EP3223865A4
(en)
|
2014-10-31 |
2018-10-03 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
|
BR112017009159A2
(en)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
methods and biomarkers to predict efficacy and evaluation of ox40 agonist treatment
|
|
CA2966523A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
US10208120B2
(en)
|
2014-11-05 |
2019-02-19 |
Genentech, Inc. |
Anti-FGFR2/3 antibodies and methods using same
|
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
|
MX2017005150A
(en)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Fc-region variants with modified fcrn- and protein a-binding properties.
|
|
RS59340B1
(en)
|
2014-11-06 |
2019-10-31 |
Hoffmann La Roche |
Fc-region variants with modified fcrn-binding and methods of use
|
|
JP6929771B2
(en)
|
2014-11-10 |
2021-09-01 |
ジェネンテック， インコーポレイテッド |
Anti-interleukin-33 antibody and its use
|
|
WO2016077369A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Animal model for nephropathy and agents for treating the same
|
|
US10160795B2
(en)
|
2014-11-14 |
2018-12-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to Ebola virus glycoprotein and their use
|
|
WO2016075278A1
(en)
|
2014-11-14 |
2016-05-19 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer
|
|
EP3221360A1
(en)
|
2014-11-17 |
2017-09-27 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
EP3221364B1
(en)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
PL3221349T3
(en)
|
2014-11-19 |
2021-05-17 |
Axon Neuroscience Se |
Humanized tau antibodies in alzheimer's disease
|
|
RU2753902C2
(en)
|
2014-11-20 |
2021-08-24 |
Ф.Хоффманн-Ля Рош Аг |
Combination therapy based on t-cell-activating bispecific antigen-binding molecules against cd3 and folate receptor 1 (folr1) and antagonists binding to pd-1 axis
|
|
JP6721590B2
(en)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Multispecific antibody
|
|
CN107108739B
(en)
|
2014-12-05 |
2022-01-04 |
豪夫迈·罗氏有限公司 |
anti-CD 79b antibodies and methods of use
|
|
CN107207591A
(en)
|
2014-12-10 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
Blood-brain barrier receptor antibody and application method
|
|
SI3233921T1
(en)
|
2014-12-19 |
2022-01-31 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antibodies and methods of use
|
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
CN107428833B
(en)
|
2015-01-16 |
2021-11-02 |
朱诺治疗学股份有限公司 |
ROR 1-specific antibodies and chimeric antigen receptors
|
|
CN113956354A
(en)
|
2015-01-22 |
2022-01-21 |
中外制药株式会社 |
Combinations and methods of use of two or more anti-C5 antibodies
|
|
CN107407677B
(en)
|
2015-01-28 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
Gene expression markers and treatment of multiple sclerosis
|
|
CN107636170A
(en)
|
2015-02-04 |
2018-01-26 |
健泰科生物技术公司 |
Saltant type Smoothened and its application method
|
|
KR20170110129A
(en)
|
2015-02-05 |
2017-10-10 |
추가이 세이야쿠 가부시키가이샤 |
Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use
|
|
KR20170140180A
(en)
|
2015-02-24 |
2017-12-20 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
|
WO2016149276A1
(en)
|
2015-03-16 |
2016-09-22 |
Genentech, Inc. |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
US10562960B2
(en)
|
2015-03-20 |
2020-02-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to gp120 and their use
|
|
PT3274370T
(en)
|
2015-03-23 |
2020-01-30 |
Bayer Pharma AG |
Anti-ceacam6 antibodies and uses thereof
|
|
JP6944924B2
(en)
|
2015-03-23 |
2021-10-06 |
ジョンス セラピューティクス， インコーポレイテッド |
Antibodies to ICOS
|
|
MY186708A
(en)
|
2015-04-03 |
2021-08-11 |
Eureka Therapeutics Inc |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
|
EP3286315B1
(en)
|
2015-04-24 |
2021-05-26 |
F. Hoffmann-La Roche AG |
Methods of identifying bacteria comprising binding polypeptides
|
|
EP3288981A1
(en)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
|
EP3936524A3
(en)
|
2015-05-11 |
2022-06-15 |
F. Hoffmann-La Roche AG |
Compositions and methods of treating lupus nephritis
|
|
SI3294770T1
(en)
|
2015-05-12 |
2021-01-29 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
|
AU2016270625B2
(en)
|
2015-05-29 |
2022-10-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP3763827A1
(en)
|
2015-05-29 |
2021-01-13 |
F. Hoffmann-La Roche AG |
Pd-l1 promoter methylation in cancer
|
|
JP2018520658A
(en)
|
2015-05-29 |
2018-08-02 |
ジェネンテック， インコーポレイテッド |
Humanized anti-Ebola virus glycoprotein antibodies and uses thereof
|
|
WO2016196679A1
(en)
|
2015-06-02 |
2016-12-08 |
Genentech, Inc. |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
ES2834823T3
(en)
|
2015-06-04 |
2021-06-18 |
Ospedale San Raffaele Srl |
IGFBP3 and its uses
|
|
WO2016193497A1
(en)
|
2015-06-04 |
2016-12-08 |
Ospedale San Raffaele Srl |
Inhibitor of igfbp3/tmem219 axis and diabetes
|
|
SG10201911349YA
(en)
|
2015-06-05 |
2020-01-30 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
|
CN107810011A
(en)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
Use the method for anti-OX40 antibodies for treating cancer
|
|
AU2016274584A1
(en)
|
2015-06-08 |
2018-01-04 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
|
|
AR104987A1
(en)
|
2015-06-15 |
2017-08-30 |
Genentech Inc |
ANTIBODY-DRUG IMMUNOCUJADOS UNITED BY NON-PEPTIDIC LINKERS
|
|
WO2016205200A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cll-1 antibodies and methods of use
|
|
LT3310814T
(en)
|
2015-06-16 |
2023-10-10 |
F. Hoffmann-La Roche Ag |
Humanized and affinity matured antibodies to fcrh5 and methods of use
|
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
CN107771076A
(en)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
Use the axle binding antagonists of PD 1 and the method for Taxane treatment Locally Advanced or metastatic breast cancer
|
|
MX2017016169A
(en)
|
2015-06-17 |
2018-08-15 |
Genentech Inc |
Anti-her2 antibodies and methods of use.
|
|
CA2987797A1
(en)
|
2015-06-17 |
2016-12-22 |
Christopher Robert Bebbington |
Methods and compositions for treating fibrotic diseases
|
|
ES2908009T3
(en)
|
2015-06-24 |
2022-04-27 |
Hoffmann La Roche |
Affinity-matched anti-transferrin receptor antibodies
|
|
MX2017016645A
(en)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Type ii anti-cd20 antibody for use in organ transplantation.
|
|
ES2898065T3
(en)
|
2015-06-29 |
2022-03-03 |
Ventana Med Syst Inc |
Materials and Procedures for Performing Histochemical Assays for Human Proepiregulin and Amphiregulin
|
|
CN105384825B
(en)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
|
|
JP6914919B2
(en)
|
2015-08-28 |
2021-08-04 |
ジェネンテック， インコーポレイテッド |
Anti-hypusine antibody and its use
|
|
CA2999369C
(en)
|
2015-09-22 |
2023-11-07 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
|
IL257565B1
(en)
|
2015-09-23 |
2024-04-01 |
Genentech Inc |
Optimized variants of anti-vegf antibodies
|
|
EP3662930A1
(en)
|
2015-09-24 |
2020-06-10 |
AbVitro LLC |
Hiv antibody compositions and methods of use
|
|
AR106188A1
(en)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
|
|
MA43345A
(en)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
|
|
AR106189A1
(en)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
|
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
|
AU2016329120B2
(en)
|
2015-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for a costimulatory TNF receptor
|
|
DK3356411T3
(en)
|
2015-10-02 |
2021-09-06 |
Hoffmann La Roche |
Bispecific antibodies specific for PD1 and TIM3
|
|
JP6657392B2
(en)
|
2015-10-02 |
2020-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Bispecific anti-human CD20 / human transferrin receptor antibodies and methods of use
|
|
JP2018529747A
(en)
|
2015-10-06 |
2018-10-11 |
ジェネンテック， インコーポレイテッド |
Methods for treating multiple sclerosis
|
|
CR20180171A
(en)
|
2015-10-07 |
2018-05-03 |
Hoffmann La Roche |
BIESPECTIFIC ANTIBODIES WITH TETRAVALENCE FOR A FNT CO-STIMULATOR RECEIVER
|
|
US10392441B2
(en)
|
2015-10-07 |
2019-08-27 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
EP3365372A1
(en)
|
2015-10-22 |
2018-08-29 |
Jounce Therapeutics, Inc. |
Gene signatures for determining icos expression
|
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
|
MX2018005036A
(en)
|
2015-10-29 |
2018-08-01 |
Hoffmann La Roche |
Anti-variant fc-region antibodies and methods of use.
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
EP3368074A2
(en)
|
2015-10-30 |
2018-09-05 |
Hoffmann-La Roche AG |
Anti-factor d antibodies and conjugates
|
|
CN115160439A
(en)
|
2015-10-30 |
2022-10-11 |
豪夫迈·罗氏有限公司 |
anti-HtrA 1 antibodies and methods of use thereof
|
|
EP4011911A1
(en)
|
2015-11-03 |
2022-06-15 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Neutralizing antibodies to hiv-1 gp41 and their use
|
|
EP3371217A1
(en)
|
2015-11-08 |
2018-09-12 |
H. Hoffnabb-La Roche Ag |
Methods of screening for multispecific antibodies
|
|
SG11201804134YA
(en)
|
2015-11-23 |
2018-06-28 |
Five Prime Therapeutics Inc |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
|
AU2016372930B2
(en)
|
2015-12-18 |
2020-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-C5 antibodies and methods of use
|
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
|
BR112018014762A2
(en)
|
2016-01-20 |
2018-12-26 |
Genentech Inc |
method of treating (early) alzheimer's disease
|
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
|
CN109196121B
(en)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
Methods for treatment and diagnosis of cancer
|
|
CA3016552A1
(en)
|
2016-03-15 |
2017-09-21 |
Genentech, Inc. |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
|
EP3443004A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3 antibodies and methods of use
|
|
CA3021086C
(en)
|
2016-04-15 |
2023-10-17 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
|
KR20190003958A
(en)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
Treatment and monitoring of cancer
|
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
|
MA56474A
(en)
|
2016-05-02 |
2022-05-11 |
Hoffmann La Roche |
CONTORSBODY - SINGLE CHAIN TARGET BINDER
|
|
JP7089483B2
(en)
|
2016-05-11 |
2022-06-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Modified anti-tenascin antibody and usage
|
|
EP3455254B1
(en)
|
2016-05-11 |
2021-07-07 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
|
HRP20221298T1
(en)
|
2016-05-13 |
2022-12-23 |
Bioatla, Inc. |
Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
EP3458101B1
(en)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac antibody conjugates and methods of use
|
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
|
CN116143918A
(en)
|
2016-06-24 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
Anti-polyubiquitin multispecific antibodies
|
|
JP6983824B2
(en)
|
2016-07-04 |
2021-12-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
New antibody format
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
KR102553195B1
(en)
|
2016-07-29 |
2023-07-07 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Anti-idiotypic antibodies to anti-CD19 antibodies
|
|
MX2018015721A
(en)
|
2016-07-29 |
2019-05-27 |
Chugai Pharmaceutical Co Ltd |
Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity.
|
|
EP3494991A4
(en)
|
2016-08-05 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for prophylaxis or treatment of il-8 related diseases
|
|
CN109476748B
(en)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
Methods for treatment and diagnosis of cancer
|
|
AU2017321973A1
(en)
|
2016-09-02 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
|
EP3510046A4
(en)
|
2016-09-07 |
2020-05-06 |
The Regents of the University of California |
Antibodies to oxidation-specific epitopes
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
EP3515932B1
(en)
|
2016-09-19 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Complement factor based affinity chromatography
|
|
SI3528838T1
(en)
|
2016-09-23 |
2023-10-30 |
F. Hoffmann-La Roche Ag |
Uses of il-13 antagonists for treating atopic dermatitis
|
|
EP3519433A1
(en)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
|
JP7050770B2
(en)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Method for preparing antibody drug conjugate
|
|
TWI775781B
(en)
|
2016-10-06 |
2022-09-01 |
美商建南德克公司 |
Therapeutic and diagnostic methods for cancer
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
US11555076B2
(en)
|
2016-10-29 |
2023-01-17 |
Genentech, Inc. |
Anti-MIC antibodies and methods of use
|
|
HUE057559T2
(en)
|
2016-11-02 |
2022-06-28 |
Jounce Therapeutics Inc |
Antibodies to pd-1 and uses thereof
|
|
AU2017361081A1
(en)
|
2016-11-15 |
2019-05-23 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
JOP20190100A1
(en)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
Anti-gitr antigen-binding proteins and methods of use thereof
|
|
EP4015532A1
(en)
|
2016-11-21 |
2022-06-22 |
cureab GmbH |
Anti-gp73 antibodies and immunoconjugates
|
|
AU2017373889A1
(en)
|
2016-12-07 |
2019-06-06 |
Ac Immune Sa |
Anti-Tau antibodies and methods of use
|
|
AU2017373884A1
(en)
|
2016-12-07 |
2019-05-30 |
Ac Immune Sa |
Anti-tau antibodies and methods of their use
|
|
KR20190095921A
(en)
|
2016-12-12 |
2019-08-16 |
제넨테크, 인크. |
How to Treat Cancer Using Anti-PD-L1 Antibody and Antiandrogen
|
|
KR20190097039A
(en)
|
2016-12-19 |
2019-08-20 |
에프. 호프만-라 로슈 아게 |
Combination Therapy with Targeted 4-1BB (CD137) Agonists
|
|
CA3039446A1
(en)
|
2016-12-20 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
|
JOP20190134A1
(en)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
Anti-neuropilin antigen-binding proteins and methods of use thereof
|
|
MX2019007795A
(en)
|
2017-01-03 |
2019-08-16 |
Hoffmann La Roche |
Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9.
|
|
WO2018129029A1
(en)
|
2017-01-04 |
2018-07-12 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
|
EP3568468A4
(en)
|
2017-01-12 |
2020-12-30 |
Eureka Therapeutics, Inc. |
Constructs targeting histone h3 peptide/mhc complexes and uses thereof
|
|
US11021535B2
(en)
|
2017-02-10 |
2021-06-01 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
CA3051700A1
(en)
|
2017-02-10 |
2018-08-16 |
Genentech, Inc. |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
|
CN110546277A
(en)
|
2017-03-01 |
2019-12-06 |
豪夫迈·罗氏有限公司 |
Methods for diagnosis and treatment of cancer
|
|
EP3600442A1
(en)
|
2017-03-22 |
2020-02-05 |
Genentech, Inc. |
Optimized antibody compositions for treatment of ocular disorders
|
|
EP3601337A1
(en)
|
2017-03-28 |
2020-02-05 |
Genentech, Inc. |
Methods of treating neurodegenerative diseases
|
|
JP7196094B2
(en)
|
2017-03-29 |
2022-12-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Bispecific Antigen Binding Molecules for Costimulatory TNF Receptors
|
|
EP3601346A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
JOP20190203A1
(en)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
Anti-tigit antigen-binding proteins and methods of use thereof
|
|
CN110494452B
(en)
|
2017-04-03 |
2023-08-25 |
豪夫迈·罗氏有限公司 |
Antibodies that bind STEAP-1
|
|
CR20190427A
(en)
|
2017-04-04 |
2019-11-01 |
Hoffmann La Roche |
Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
|
|
JP6997212B2
(en)
|
2017-04-05 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Bispecific antibodies that specifically bind to PD1 and LAG3
|
|
CN110392698B
(en)
|
2017-04-05 |
2022-01-25 |
豪夫迈·罗氏有限公司 |
anti-LAG 3 antibodies
|
|
CA3058478A1
(en)
|
2017-04-14 |
2018-10-18 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
CA3059615A1
(en)
|
2017-04-21 |
2018-10-25 |
Genentech, Inc. |
Use of klk5 antagonists for treatment of a disease
|
|
KR20200012860A
(en)
|
2017-04-26 |
2020-02-05 |
유레카 쎄라퓨틱스, 인코포레이티드 |
Constructs that specifically recognize glypican 3 and uses thereof
|
|
US20220135670A1
(en)
|
2017-04-27 |
2022-05-05 |
Tesaro, Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
EA201992626A1
(en)
|
2017-05-05 |
2020-04-24 |
Аллакос Инк. |
METHODS AND COMPOSITIONS FOR TREATMENT OF ALLERGIC EYE DISEASES
|
|
CA3062177A1
(en)
|
2017-05-16 |
2018-11-22 |
Five Prime Therapeutics, Inc. |
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
|
|
JP2020527351A
(en)
|
2017-07-21 |
2020-09-10 |
ジェネンテック， インコーポレイテッド |
Cancer treatment and diagnosis
|
|
AU2018308364C1
(en)
|
2017-07-26 |
2023-02-16 |
Forty Seven, Inc. |
Anti-SIRP-alpha antibodies and related methods
|
|
WO2019059411A1
(en)
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
|
KR20200104284A
(en)
|
2017-10-03 |
2020-09-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
HPV-specific binding molecule
|
|
EP3694890A4
(en)
|
2017-10-12 |
2021-11-03 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
|
CN111246884A
(en)
|
2017-11-01 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
Novel antigen binding molecules comprising trimers of TNF family ligands
|
|
AU2018359506A1
(en)
|
2017-11-01 |
2020-04-23 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted OX40 agonists
|
|
AU2018357923A1
(en)
|
2017-11-01 |
2020-03-05 |
F. Hoffmann-La Roche Ag |
Bispecific 2+1 contorsbodies
|
|
MX2020004243A
(en)
|
2017-11-01 |
2020-09-25 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen.
|
|
TW201923089A
(en)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
Diagnostic and therapeutic methods for cancer
|
|
CN111615520A
(en)
|
2017-12-01 |
2020-09-01 |
辉瑞大药厂 |
anti-CXCR 5 antibodies and compositions and uses thereof
|
|
KR20200110745A
(en)
|
2017-12-15 |
2020-09-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Anti-CCT5 binding molecule and method of use thereof
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
AU2018390881A1
(en)
|
2017-12-21 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to HLA-A2/WT1
|
|
TW201929907A
(en)
|
2017-12-22 |
2019-08-01 |
美商建南德克公司 |
Use of PILRA binding agents for treatment of a Disease
|
|
EP4219559A3
(en)
|
2017-12-22 |
2023-10-18 |
Jounce Therapeutics, Inc. |
Antibodies for lilrb2
|
|
US20220135687A1
(en)
|
2017-12-28 |
2022-05-05 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against pd-l1
|
|
EP3732202A4
(en)
|
2017-12-28 |
2022-06-15 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against tigit
|
|
WO2019129679A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
|
|
WO2019136029A1
(en)
|
2018-01-02 |
2019-07-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
KR20200106525A
(en)
|
2018-01-05 |
2020-09-14 |
에이씨 이뮨 에스.에이. |
Misfolded TDP-43 binding molecule
|
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
|
CA3088649A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
|
ES2932861T3
(en)
|
2018-01-26 |
2023-01-27 |
Hoffmann La Roche |
IL-22 Fc Compositions and Procedures for Use
|
|
CR20200327A
(en)
|
2018-01-26 |
2020-11-05 |
Genentech Inc |
Il-22 fc fusion proteins and methods of use
|
|
JP7438953B2
(en)
|
2018-02-01 |
2024-02-27 |
イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド |
Fully humanized anti-B cell maturation antigen (BCMA) single chain antibody and its applications
|
|
SG11202007390YA
(en)
|
2018-02-08 |
2020-08-28 |
Genentech Inc |
Bispecific antigen-binding molecules and methods of use
|
|
TWI829667B
(en)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
Antibodies binding to gprc5d
|
|
KR102417088B1
(en)
|
2018-02-09 |
2022-07-07 |
제넨테크, 인크. |
Methods of treatment and diagnosis for mast cell-mediated inflammatory diseases
|
|
EP3752530A1
(en)
|
2018-02-14 |
2020-12-23 |
ABBA Therapeutics AG |
Anti-human pd-l2 antibodies
|
|
RU2020130795A
(en)
|
2018-02-21 |
2022-03-21 |
Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз |
NEUTRALIZING ANTIBODIES TO ENV HIV-1 AND THEIR USE
|
|
EP3755364A1
(en)
|
2018-02-21 |
2020-12-30 |
F. Hoffmann-La Roche AG |
Dosing for treatment with il-22 fc fusion proteins
|
|
TW202000702A
(en)
|
2018-02-26 |
2020-01-01 |
美商建南德克公司 |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
|
KR20200132913A
(en)
|
2018-03-13 |
2020-11-25 |
에프. 호프만-라 로슈 아게 |
Therapeutic combination of 4-1BB agonist and anti-CD20 antibody
|
|
TW202003561A
(en)
|
2018-03-13 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
Combination therapy with targeted 4-1BB (CD137) agonists
|
|
AU2019235033A1
(en)
|
2018-03-14 |
2020-07-30 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Anti-claudin 18.2 antibodies
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
CA3093729A1
(en)
|
2018-03-15 |
2019-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
|
PE20210290A1
(en)
|
2018-03-21 |
2021-02-11 |
Five Prime Therapeutics Inc |
SIGHT BINDING ANTIBODIES AT ACID pH
|
|
AU2019245243A1
(en)
|
2018-03-29 |
2020-09-03 |
Genentech, Inc |
Modulating lactogenic activity in mammalian cells
|
|
TW202011029A
(en)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
Methods for detecting and quantifying FGF21
|
|
MA52193A
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics Inc |
T-LYMPHOCYTE RECEPTORS AND MODIFIED CELLS EXPRESSING THEM
|
|
JP7418346B2
(en)
|
2018-04-13 |
2024-01-19 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Her2-targeted antigen-binding molecule including 4-1BBL
|
|
WO2019222294A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
CA3100007A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
HRP20230787T1
(en)
|
2018-05-18 |
2023-10-27 |
Glycotope Gmbh |
Anti-muc1 antibody
|
|
EP3805400A4
(en)
|
2018-06-04 |
2022-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule showing changed half-life in cytoplasm
|
|
WO2019246557A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
JP2021528988A
(en)
|
2018-07-04 |
2021-10-28 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
New bispecific agonist 4-1BB antigen-binding molecule
|
|
SG11202100096XA
(en)
|
2018-07-09 |
2021-02-25 |
Five Prime Therapeutics Inc |
Antibodies binding to ilt4
|
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
|
BR112021000303A2
(en)
|
2018-07-11 |
2021-04-13 |
Five Prime Therapeutics, Inc. |
ANTIBODIES THAT BIND THE SIGHT IN ACID PH
|
|
KR20210034622A
(en)
|
2018-07-18 |
2021-03-30 |
제넨테크, 인크. |
Lung cancer treatment method using PD-1 axis binding antagonist, anti-metabolite, and platinum agent
|
|
TW202017944A
(en)
|
2018-07-20 |
2020-05-16 |
美商表面腫瘤學公司 |
Anti-cd112r compositions and methods
|
|
SG11202101152QA
(en)
|
2018-08-03 |
2021-03-30 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
|
EP3608674A1
(en)
|
2018-08-09 |
2020-02-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
|
|
SG11202003531WA
(en)
|
2018-08-10 |
2020-05-28 |
Chugai Pharmaceutical Co Ltd |
Anti-cd137 antigen-binding molecule and utilization thereof
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
EP4249917A3
(en)
|
2018-09-21 |
2023-11-08 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
|
CN113286812A
(en)
|
2018-09-27 |
2021-08-20 |
西里欧发展公司 |
Masked cytokine polypeptides
|
|
SG11202102477QA
(en)
|
2018-10-01 |
2021-04-29 |
Hoffmann La Roche |
Bispecific antigen binding molecules comprising anti-fap clone 212
|
|
CN112654641A
(en)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
Bispecific antigen binding molecules with trivalent binding to CD40
|
|
EP3632929A1
(en)
|
2018-10-02 |
2020-04-08 |
Ospedale San Raffaele S.r.l. |
Antibodies and uses thereof
|
|
US20220010020A1
(en)
|
2018-10-05 |
2022-01-13 |
Five Prime Therapeutics, Inc. |
Anti-FGFR2 Antibody Formulations
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
CN113196061A
(en)
|
2018-10-18 |
2021-07-30 |
豪夫迈·罗氏有限公司 |
Methods of diagnosis and treatment of sarcoma-like renal cancer
|
|
US20210395390A1
(en)
|
2018-10-31 |
2021-12-23 |
Bayer Aktiengesellschaft |
Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
|
|
SG11202105010UA
(en)
|
2018-11-16 |
2021-06-29 |
Memorial Sloan Kettering Cancer Center |
Antibodies to mucin-16 and methods of use thereof
|
|
MX2021006578A
(en)
|
2018-12-05 |
2021-07-07 |
Genentech Inc |
Diagnostic methods and compositions for cancer immunotherapy.
|
|
BR112021010908A2
(en)
|
2018-12-06 |
2021-08-31 |
Genentech, Inc. |
METHOD FOR TREATMENT OF DIFFUSED LARGE B-CELL LYMPHOMA, KIT AND IMMUNOCONJUGATE
|
|
CN113227119A
(en)
|
2018-12-10 |
2021-08-06 |
基因泰克公司 |
Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
|
|
EP3898667A2
(en)
|
2018-12-20 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Modified antibody fcs and methods of use
|
|
US20220089694A1
(en)
|
2018-12-20 |
2022-03-24 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
|
WO2020127618A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Tumor-targeted agonistic cd28 antigen binding molecules
|
|
EP3898671A1
(en)
|
2018-12-21 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Antibody that binds to vegf and il-1beta and methods of use
|
|
SG11202102859TA
(en)
|
2018-12-21 |
2021-04-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
|
AR117728A1
(en)
|
2018-12-21 |
2021-08-25 |
Hoffmann La Roche |
CD28 ANTIGEN BINDING SUPERAGONIST MOLECULES WITH TUMOR TARGET
|
|
MX2021007769A
(en)
|
2018-12-26 |
2021-09-23 |
Xilio Dev Inc |
Activatable masked anti-ctla4 binding proteins.
|
|
JP2022515543A
(en)
|
2018-12-30 |
2022-02-18 |
エフ．ホフマン－ラ ロシュ アーゲー |
Anti-rabbit CD19 antibody and how to use
|
|
CN115120716A
(en)
|
2019-01-14 |
2022-09-30 |
健泰科生物技术公司 |
Methods of treating cancer with PD-1 axis binding antagonists and RNA vaccines
|
|
CA3126778A1
(en)
|
2019-01-17 |
2020-07-23 |
Bayer Aktiengesellschaft |
Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
|
|
CN113329770A
(en)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
Novel cancer antigen and antibody against said antigen
|
|
US20220096651A1
(en)
|
2019-01-29 |
2022-03-31 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
CA3130695A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
|
MX2021010565A
(en)
|
2019-03-08 |
2021-10-13 |
Genentech Inc |
Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles.
|
|
TW202100556A
(en)
|
2019-03-14 |
2021-01-01 |
美商建南德克公司 |
Treatment with her2 t cell-dependent bispecific antibodies
|
|
WO2020208049A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising lipocalin muteins
|
|
AU2020257748A1
(en)
|
2019-04-19 |
2021-11-18 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor recognizing modification site of antibody
|
|
AU2020258480A1
(en)
|
2019-04-19 |
2021-10-21 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
|
CN114269376A
(en)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
Methods of treating cancer with anti-PD-L1 antibodies
|
|
WO2020227228A2
(en)
|
2019-05-03 |
2020-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
CN114450022A
(en)
|
2019-05-14 |
2022-05-06 |
狼人治疗公司 |
Separation fraction and method of use thereof
|
|
CN114206340A
(en)
|
2019-05-14 |
2022-03-18 |
豪夫迈·罗氏有限公司 |
Methods of treating follicular lymphoma using anti-CD 79B immunoconjugates
|
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
|
AU2020278907A1
(en)
|
2019-05-23 |
2022-01-20 |
Ac Immune Sa |
Anti-TDP-43 binding molecules and uses thereof
|
|
JP2022538075A
(en)
|
2019-06-26 |
2022-08-31 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Fusion of antibody-bound CEA and 4-1BBL
|
|
WO2020260326A1
(en)
|
2019-06-27 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
|
WO2021003297A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
|
AR119382A1
(en)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
PRE-TARGETING ANTIBODIES AND METHODS OF USE
|
|
AR119393A1
(en)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
ANTIBODIES THAT BIND NKG2D
|
|
CA3144524A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
CN114174338A
(en)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
Antibodies that bind to GPRC5D
|
|
KR102509648B1
(en)
|
2019-08-06 |
2023-03-15 |
아프리노이아 테라퓨틱스 리미티드 |
Antibodies that bind to pathological Tau species and uses thereof
|
|
CN114340675A
(en)
|
2019-09-12 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
Compositions and methods for treating lupus nephritis
|
|
CA3150999A1
(en)
|
2019-09-18 |
2021-03-25 |
James Thomas Koerber |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
JP2022548292A
(en)
|
2019-09-19 |
2022-11-17 |
ブリストル－マイヤーズ スクイブ カンパニー |
Antibodies that bind VISTA at acidic pH
|
|
JP2022549218A
(en)
|
2019-09-20 |
2022-11-24 |
ジェネンテック， インコーポレイテッド |
Anti-tryptase antibody medication
|
|
MX2022003610A
(en)
|
2019-09-27 |
2022-04-20 |
Genentech Inc |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies.
|
|
CN114945386A
(en)
|
2019-10-18 |
2022-08-26 |
基因泰克公司 |
Methods of treating diffuse large B-cell lymphoma using anti-CD 79B immunoconjugates
|
|
KR20220092580A
(en)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
Diagnosis and treatment methods for the treatment of blood cancer
|
|
JP2023501229A
(en)
|
2019-11-15 |
2023-01-18 |
エンテラ・エッセ・エッレ・エッレ |
TMEM219 antibody and its therapeutic use
|
|
JP2023503105A
(en)
|
2019-11-21 |
2023-01-26 |
エンテラ・エッセ・エッレ・エッレ |
IGFBP3 Antibodies and Their Therapeutic Uses
|
|
KR20220122653A
(en)
|
2019-12-06 |
2022-09-02 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Anti-idiotypic Antibodies and Related Compositions and Methods Against BPCMA-Target Binding Domains
|
|
EP4069742A1
(en)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
|
CR20220330A
(en)
|
2019-12-13 |
2022-08-04 |
Genentech Inc |
Anti-ly6g6d antibodies and methods of use
|
|
PE20221282A1
(en)
|
2019-12-18 |
2022-09-05 |
Hoffmann La Roche |
ANTIBODIES THAT BIND HLA-A2/MAGE-A4
|
|
CN113045655A
(en)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
anti-OX 40 antibodies and uses thereof
|
|
PE20221585A1
(en)
|
2019-12-27 |
2022-10-06 |
Chugai Pharmaceutical Co Ltd |
ANTI-ANTIGEN-4 ANTIBODY ASSOCIATED WITH THE CYTOTOXIC T LYMPHOCYTE (CTLA-4) AND USE THEREOF
|
|
AU2021206523A1
(en)
|
2020-01-09 |
2022-05-26 |
F. Hoffmann-La Roche Ag |
New 4-1BBL trimer-containing antigen binding molecules
|
|
CN110818795B
(en)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
anti-TIGIT antibodies and methods of use
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
JP2023513059A
(en)
|
2020-01-31 |
2023-03-30 |
ザ クリーブランド クリニック ファウンデーション |
Anti-Mullerian hormone receptor 2 antibody and method of use
|
|
JP2023512654A
(en)
|
2020-01-31 |
2023-03-28 |
ジェネンテック， インコーポレイテッド |
Methods for Inducing Neoepitope-Specific T Cells Using PD-1 Axis Binding Antagonists and RNA Vaccines
|
|
TW202144395A
(en)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
Anti-CD137 antigen-binding molecule for use in cancer treatment
|
|
IL295023A
(en)
|
2020-02-14 |
2022-09-01 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
|
EP3868396A1
(en)
|
2020-02-20 |
2021-08-25 |
Enthera S.R.L. |
Inhibitors and uses thereof
|
|
EP4093762A1
(en)
|
2020-02-20 |
2022-11-30 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Epstein-barr virus monoclonal antibodies and uses thereof
|
|
CA3169910A1
(en)
|
2020-02-28 |
2021-09-02 |
Shanghai Henlius Biotech, Inc. |
Anti-cd137 constructs, multispecific antibody and uses thereof
|
|
AU2021225920A1
(en)
|
2020-02-28 |
2022-09-15 |
Shanghai Henlius Biotech, Inc. |
Anti-CD137 construct and use thereof
|
|
CN115605507A
(en)
|
2020-03-13 |
2023-01-13 |
基因泰克公司（Us） |
Anti-interleukin-33 antibodies and uses thereof
|
|
CN117510630A
(en)
|
2020-03-19 |
2024-02-06 |
基因泰克公司 |
Isotype selective anti-TGF-beta antibodies and methods of use
|
|
EP4107185A1
(en)
|
2020-03-23 |
2022-12-28 |
Genentech, Inc. |
Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
|
|
JP2023518815A
(en)
|
2020-03-23 |
2023-05-08 |
ジェネンテック， インコーポレイテッド |
Methods of treating pneumonia, including COVID-19 pneumonia, with an IL6 antagonist
|
|
US20230174656A1
(en)
|
2020-03-23 |
2023-06-08 |
Genentech, Inc. |
Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
|
|
CR20220489A
(en)
|
2020-03-24 |
2022-10-31 |
Genentech Inc |
Tie2-binding agents and methods of use
|
|
EP4127153A2
(en)
|
2020-03-26 |
2023-02-08 |
Genentech, Inc. |
Modified mammalian cells having reduced host cell proteins
|
|
AR121706A1
(en)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES
|
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
|
IL297541A
(en)
|
2020-04-24 |
2022-12-01 |
Genentech Inc |
Methods of using anti-cd79b immunoconjugates
|
|
JP2023523145A
(en)
|
2020-04-27 |
2023-06-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Isotype-independent antibody against lipoprotein (a)
|
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
EP4146283A1
(en)
|
2020-05-03 |
2023-03-15 |
Levena (Suzhou) Biopharma Co., Ltd. |
Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
|
|
US20230220057A1
(en)
|
2020-05-27 |
2023-07-13 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
|
CN116529260A
(en)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
anti-CD 93 constructs and uses thereof
|
|
AU2021283345A1
(en)
|
2020-06-02 |
2023-02-02 |
Dynamicure Biotechnology Llc |
Anti-CD93 constructs and uses thereof
|
|
AU2021288916A1
(en)
|
2020-06-08 |
2022-11-24 |
F.Hoffmann-La Roche Ag |
Anti-HBV antibodies and methods of use
|
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
MX2022015881A
(en)
|
2020-06-18 |
2023-01-24 |
Genentech Inc |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists.
|
|
KR20230025673A
(en)
|
2020-06-19 |
2023-02-22 |
에프. 호프만-라 로슈 아게 |
Antibodies that bind to CD3 and FolR1
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
WO2021255155A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cd19
|
|
IL296089A
(en)
|
2020-06-19 |
2022-11-01 |
Hoffmann La Roche |
Antibodies binding to cd3
|
|
US20220017637A1
(en)
|
2020-06-23 |
2022-01-20 |
Hoffmann-La Roche Inc. |
Agonistic cd28 antigen binding molecules targeting her2
|
|
TW202216756A
(en)
|
2020-06-24 |
2022-05-01 |
美商建南德克公司 |
Apoptosis resistant cell lines
|
|
WO2021260064A1
(en)
|
2020-06-25 |
2021-12-30 |
F. Hoffmann-La Roche Ag |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
|
KR20230037578A
(en)
|
2020-07-10 |
2023-03-16 |
에프. 호프만-라 로슈 아게 |
Antibodies that bind to cancer cells and target radionuclides to those cells
|
|
TW202216780A
(en)
|
2020-07-17 |
2022-05-01 |
美商建南德克公司 |
Anti-notch2 antibodies and methods of use
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
KR20230133832A
(en)
|
2020-07-29 |
2023-09-19 |
다이내믹큐어 바이오테크놀로지 엘엘씨 |
Anti-CD93 constructs and uses thereof
|
|
WO2022031749A1
(en)
|
2020-08-03 |
2022-02-10 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
|
WO2022029660A1
(en)
|
2020-08-05 |
2022-02-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
|
AU2021322239A1
(en)
|
2020-08-07 |
2023-02-23 |
Genentech, Inc. |
Flt3 ligand fusion proteins and methods of use
|
|
AR123254A1
(en)
|
2020-08-14 |
2022-11-16 |
Ac Immune Sa |
HUMANIZED ANTI-TDP-43 BINDING MOLECULES AND THEIR USES
|
|
WO2022043517A2
(en)
|
2020-08-27 |
2022-03-03 |
Cureab Gmbh |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
|
CA3192344A1
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
|
EP4208201A1
(en)
|
2020-09-04 |
2023-07-12 |
F. Hoffmann-La Roche AG |
Antibody that binds to vegf-a and ang2 and methods of use
|
|
CN116249719A
(en)
|
2020-09-15 |
2023-06-09 |
拜耳公司 |
Novel anti-A2 AP antibodies and uses thereof
|
|
EP4213877A1
(en)
|
2020-09-17 |
2023-07-26 |
Genentech, Inc. |
Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
|
|
JP2023544407A
(en)
|
2020-10-05 |
2023-10-23 |
ジェネンテック， インコーポレイテッド |
Administration for treatment with anti-FcRH5/anti-CD3 bispecific antibodies
|
|
KR20230091871A
(en)
|
2020-10-20 |
2023-06-23 |
에프. 호프만-라 로슈 아게 |
Combination therapy of a PD-1 axis binding antagonist and a LRRK2 inhibitor
|
|
AR123855A1
(en)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE
|
|
EP4232475A1
(en)
|
2020-10-20 |
2023-08-30 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
IL302400A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
|
EP4240493A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
WO2022101458A1
(en)
|
2020-11-16 |
2022-05-19 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted cd40 agonists
|
|
TW202237639A
(en)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
|
|
TW202237638A
(en)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
|
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
|
JP2024503826A
(en)
|
2021-01-06 |
2024-01-29 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Combination therapy using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody
|
|
EP4277705A1
(en)
|
2021-01-12 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Split antibodies which bind to cancer cells and target radionuclides to said cells
|
|
AU2022207624A1
(en)
|
2021-01-13 |
2023-07-13 |
F. Hoffmann-La Roche Ag |
Combination therapy
|
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
CN117120084A
(en)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
Methods and means for modulating B cell mediated immune responses
|
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
|
EP4284422A1
(en)
|
2021-01-28 |
2023-12-06 |
Vaccinvent GmbH |
Method and means for modulating b-cell mediated immune responses
|
|
EP4288458A1
(en)
|
2021-02-03 |
2023-12-13 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
CN117396502A
(en)
|
2021-02-09 |
2024-01-12 |
佐治亚大学研究基金会有限公司 |
Human monoclonal antibodies to pneumococcal antigens
|
|
IL304955A
(en)
|
2021-02-09 |
2023-10-01 |
Us Health |
Antibodies targeting the spike protein of coronaviruses
|
|
CA3208365A1
(en)
|
2021-02-15 |
2022-08-18 |
Chantal KUHN |
Cell therapy compositions and methods for modulating tgf-b signaling
|
|
IL305131A
(en)
|
2021-02-26 |
2023-10-01 |
Bayer Ag |
INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDING
|
|
CA3209364A1
(en)
|
2021-03-01 |
2022-09-09 |
Jennifer O'neil |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
|
US20220306743A1
(en)
|
2021-03-01 |
2022-09-29 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
|
JP2024509169A
(en)
|
2021-03-03 |
2024-02-29 |
ソレント・セラピューティクス・インコーポレイテッド |
Antibody-drug conjugates including anti-BCMA antibodies
|
|
JP2024509191A
(en)
|
2021-03-05 |
2024-02-29 |
ダイナミキュア バイオテクノロジー エルエルシー |
Anti-VISTA constructs and their uses
|
|
AR125074A1
(en)
|
2021-03-12 |
2023-06-07 |
Genentech Inc |
ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, ANTI-KLK5/KLK7 MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE
|
|
CA3213599A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
TW202300648A
(en)
|
2021-03-25 |
2023-01-01 |
美商當康生物科技有限公司 |
Anti-igfbp7 constructs and uses thereof
|
|
US20220389096A1
(en)
|
2021-03-30 |
2022-12-08 |
Bayer Aktiengesellschaft |
Novel anti-sema3a antibodies and uses thereof
|
|
AR125344A1
(en)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
ANTI-C1S ANTIBODY
|
|
TW202305122A
(en)
|
2021-04-19 |
2023-02-01 |
美商建南德克公司 |
Modified mammalian cells
|
|
WO2022228705A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
CA3218170A1
(en)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
US20220389097A1
(en)
|
2021-05-14 |
2022-12-08 |
Genentech Inc. |
Agonists of TREM2
|
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
|
KR20240010469A
(en)
|
2021-05-21 |
2024-01-23 |
제넨테크, 인크. |
Modified cells for production of recombinant products of interest
|
|
AR126009A1
(en)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM
|
|
TW202306994A
(en)
|
2021-06-04 |
2023-02-16 |
日商中外製藥股份有限公司 |
Anti-ddr2 antibodies and uses thereof
|
|
CA3216220A1
(en)
|
2021-06-09 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
|
CA3221924A1
(en)
|
2021-06-11 |
2022-12-15 |
Genentech, Inc. |
Method for treating chronic obstructive pulmonary disease with an st2 antagonist
|
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
BR112023023480A2
(en)
|
2021-06-25 |
2024-01-30 |
Chugai Pharmaceutical Co Ltd |
USE OF ANTI-CTLA-4 ANTIBODY
|
|
WO2022270611A1
(en)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
Anti–ctla-4 antibody
|
|
TW202317633A
(en)
|
2021-07-08 |
2023-05-01 |
美商舒泰神（加州）生物科技有限公司 |
Antibodies specifically recognizing tnfr2 and uses thereof
|
|
WO2023288182A1
(en)
|
2021-07-12 |
2023-01-19 |
Genentech, Inc. |
Structures for reducing antibody-lipase binding
|
|
US20230049152A1
(en)
|
2021-07-14 |
2023-02-16 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
|
CN115812082A
(en)
|
2021-07-14 |
2023-03-17 |
舒泰神（北京）生物制药股份有限公司 |
Antibody specifically recognizing CD40 and application thereof
|
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
|
WO2023001884A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
|
CN117794953A
(en)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
Bispecific antibodies and methods of use
|
|
WO2023019092A1
(en)
|
2021-08-07 |
2023-02-16 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
|
WO2023021055A1
(en)
|
2021-08-19 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
Multivalent anti-variant fc-region antibodies and methods of use
|
|
AU2022332285A1
(en)
|
2021-08-23 |
2024-02-15 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
IL310382A
(en)
|
2021-08-27 |
2024-03-01 |
Genentech Inc |
Methods of treating tau pathologies
|
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
|
AU2022345251A1
(en)
|
2021-09-17 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
WO2023081818A1
(en)
|
2021-11-05 |
2023-05-11 |
American Diagnostics & Therapy, Llc (Adxrx) |
Monoclonal antibodies against carcinoembryonic antigens, and their uses
|
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
TW202337494A
(en)
|
2021-11-16 |
2023-10-01 |
美商建南德克公司 |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
|
WO2023088959A1
(en)
|
2021-11-16 |
2023-05-25 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
|
WO2023094569A1
(en)
|
2021-11-26 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
|
AR127887A1
(en)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
ANTIBODIES THAT BIND CD3 AND PLAP
|
|
TW202340248A
(en)
|
2021-12-20 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
Agonistic ltbr antibodies and bispecific antibodies comprising them
|
|
US20230227545A1
(en)
|
2022-01-07 |
2023-07-20 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
|
US20230322958A1
(en)
|
2022-01-19 |
2023-10-12 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Conjugates and Methods of Use
|
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
|
WO2023156549A1
(en)
|
2022-02-16 |
2023-08-24 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
|
WO2023159182A1
(en)
|
2022-02-18 |
2023-08-24 |
Rakuten Medical, Inc. |
Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
|
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
TW202346365A
(en)
|
2022-03-23 |
2023-12-01 |
瑞士商赫孚孟拉羅股份公司 |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
WO2023192827A1
(en)
|
2022-03-26 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to hiv-1 env and their use
|
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
|
WO2023203177A1
(en)
|
2022-04-20 |
2023-10-26 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
|
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
|
WO2023217933A1
(en)
|
2022-05-11 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antibody that binds to vegf-a and il6 and methods of use
|
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
|
WO2023237706A2
(en)
|
2022-06-08 |
2023-12-14 |
Institute For Research In Biomedicine (Irb) |
Cross-specific antibodies, uses and methods for discovery thereof
|
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
|
WO2024020579A1
(en)
|
2022-07-22 |
2024-01-25 |
Bristol-Myers Squibb Company |
Antibodies binding to human pad4 and uses thereof
|
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|